Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: OAS3

Gene summary for OAS3

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

OAS3

Gene ID

4940

Gene name2'-5'-oligoadenylate synthetase 3
Gene Aliasp100
Cytomap12q24.13
Gene Typeprotein-coding
GO ID

GO:0001816

UniProtAcc

Q9Y6K5


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
4940OAS3LZE4THumanEsophagusESCC2.57e-041.68e-010.0811
4940OAS3LZE7THumanEsophagusESCC1.36e-051.78e-010.0667
4940OAS3LZE20THumanEsophagusESCC3.83e-114.29e-010.0662
4940OAS3LZE24THumanEsophagusESCC5.63e-259.33e-010.0596
4940OAS3LZE21THumanEsophagusESCC5.69e-032.42e-010.0655
4940OAS3P1T-EHumanEsophagusESCC4.19e-131.01e+000.0875
4940OAS3P2T-EHumanEsophagusESCC1.13e-561.10e+000.1177
4940OAS3P4T-EHumanEsophagusESCC5.08e-255.65e-010.1323
4940OAS3P5T-EHumanEsophagusESCC6.01e-163.13e-010.1327
4940OAS3P8T-EHumanEsophagusESCC1.24e-225.35e-010.0889
4940OAS3P9T-EHumanEsophagusESCC1.90e-214.39e-010.1131
4940OAS3P11T-EHumanEsophagusESCC9.48e-221.01e+000.1426
4940OAS3P15T-EHumanEsophagusESCC3.06e-081.57e-010.1149
4940OAS3P17T-EHumanEsophagusESCC2.02e-167.02e-010.1278
4940OAS3P20T-EHumanEsophagusESCC3.53e-175.17e-010.1124
4940OAS3P21T-EHumanEsophagusESCC2.01e-459.77e-010.1617
4940OAS3P22T-EHumanEsophagusESCC5.30e-111.87e-010.1236
4940OAS3P23T-EHumanEsophagusESCC5.32e-165.69e-010.108
4940OAS3P24T-EHumanEsophagusESCC3.44e-255.35e-010.1287
4940OAS3P26T-EHumanEsophagusESCC1.45e-092.14e-010.1276
Page: 1 2 3 4 5 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:00343405Oral cavityOSCCresponse to type I interferon46/730558/187234.17e-101.11e-0846
GO:00603374Oral cavityOSCCtype I interferon signaling pathway41/730550/187235.59e-101.46e-0841
GO:00713574Oral cavityOSCCcellular response to type I interferon42/730552/187238.50e-102.13e-0842
GO:003052218Oral cavityOSCCintracellular receptor signaling pathway149/7305265/187238.69e-091.81e-07149
GO:00028317Oral cavityOSCCregulation of response to biotic stimulus177/7305327/187231.73e-083.43e-07177
GO:00320697Oral cavityOSCCregulation of nuclease activity20/730522/187236.02e-078.64e-0620
GO:00019594Oral cavityOSCCregulation of cytokine-mediated signaling pathway87/7305150/187231.82e-062.35e-0587
GO:00603384Oral cavityOSCCregulation of type I interferon-mediated signaling pathway28/730536/187232.45e-063.08e-0528
GO:00607594Oral cavityOSCCregulation of response to cytokine stimulus92/7305162/187233.25e-063.90e-0592
GO:00028324Oral cavityOSCCnegative regulation of response to biotic stimulus65/7305108/187236.62e-067.29e-0565
GO:00022214Oral cavityOSCCpattern recognition receptor signaling pathway95/7305172/187231.11e-051.15e-0495
GO:00450717Oral cavityOSCCnegative regulation of viral genome replication38/730556/187231.15e-051.18e-0438
GO:00027537Oral cavityOSCCcytoplasmic pattern recognition receptor signaling pathway40/730560/187231.32e-051.33e-0440
GO:00450884Oral cavityOSCCregulation of innate immune response116/7305218/187231.36e-051.37e-04116
GO:00485259Oral cavityOSCCnegative regulation of viral process56/730592/187231.77e-051.72e-0456
GO:00326083Oral cavityOSCCinterferon-beta production37/730556/187233.74e-053.32e-0437
GO:00326483Oral cavityOSCCregulation of interferon-beta production37/730556/187233.74e-053.32e-0437
GO:00324816Oral cavityOSCCpositive regulation of type I interferon production38/730558/187233.91e-053.43e-0438
GO:00327283Oral cavityOSCCpositive regulation of interferon-beta production27/730539/187231.27e-049.09e-0427
GO:00395283Oral cavityOSCCcytoplasmic pattern recognition receptor signaling pathway in response to virus24/730534/187231.89e-041.28e-0324
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa05169210EsophagusESCCEpstein-Barr virus infection151/4205202/84651.55e-133.45e-121.77e-12151
hsa0516425EsophagusESCCInfluenza A122/4205171/84655.01e-094.79e-082.45e-08122
hsa05171211EsophagusESCCCoronavirus disease - COVID-19156/4205232/84653.18e-082.68e-071.37e-07156
hsa051609EsophagusESCCHepatitis C107/4205157/84651.75e-061.08e-055.55e-06107
hsa051629EsophagusESCCMeasles90/4205139/84652.16e-047.87e-044.03e-0490
hsa0462122EsophagusESCCNOD-like receptor signaling pathway116/4205186/84652.90e-041.03e-035.30e-04116
hsa0516937EsophagusESCCEpstein-Barr virus infection151/4205202/84651.55e-133.45e-121.77e-12151
hsa0516435EsophagusESCCInfluenza A122/4205171/84655.01e-094.79e-082.45e-08122
hsa05171310EsophagusESCCCoronavirus disease - COVID-19156/4205232/84653.18e-082.68e-071.37e-07156
hsa0516016EsophagusESCCHepatitis C107/4205157/84651.75e-061.08e-055.55e-06107
hsa0516213EsophagusESCCMeasles90/4205139/84652.16e-047.87e-044.03e-0490
hsa0462132EsophagusESCCNOD-like receptor signaling pathway116/4205186/84652.90e-041.03e-035.30e-04116
hsa0517142LiverHCCCoronavirus disease - COVID-19167/4020232/84651.50e-144.19e-132.33e-13167
hsa0516921LiverHCCEpstein-Barr virus infection128/4020202/84653.17e-062.79e-051.55e-05128
hsa0516021LiverHCCHepatitis C94/4020157/84651.11e-034.10e-032.28e-0394
hsa0516421LiverHCCInfluenza A101/4020171/84651.41e-035.07e-032.82e-03101
hsa0517152LiverHCCCoronavirus disease - COVID-19167/4020232/84651.50e-144.19e-132.33e-13167
hsa0516931LiverHCCEpstein-Barr virus infection128/4020202/84653.17e-062.79e-051.55e-05128
hsa0516031LiverHCCHepatitis C94/4020157/84651.11e-034.10e-032.28e-0394
hsa0516431LiverHCCInfluenza A101/4020171/84651.41e-035.07e-032.82e-03101
Page: 1 2 3 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
OAS3SNVMissense_Mutationc.1527N>Tp.Gln509Hisp.Q509HQ9Y6K5protein_codingdeleterious(0.03)benign(0.069)TCGA-A8-A097-01Breastbreast invasive carcinomaFemale>=65I/IIHormone TherapytamoxiphenSD
OAS3SNVMissense_Mutationnovelc.2035N>Ap.Glu679Lysp.E679KQ9Y6K5protein_codingtolerated(0.08)possibly_damaging(0.622)TCGA-AR-A2LE-01Breastbreast invasive carcinomaFemale>=65I/IIHormone TherapytamoxiphenPD
OAS3SNVMissense_Mutationnovelc.473N>Tp.Ser158Phep.S158FQ9Y6K5protein_codingtolerated(0.05)benign(0.282)TCGA-BH-A2L8-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapycytoxanCR
OAS3SNVMissense_Mutationc.1760N>Tp.Arg587Leup.R587LQ9Y6K5protein_codingdeleterious(0)possibly_damaging(0.758)TCGA-EW-A6SD-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapytchSD
OAS3insertionFrame_Shift_Insnovelc.2563_2564insTCTCCAGTCACAAAp.Gln855LeufsTer22p.Q855Lfs*22Q9Y6K5protein_codingTCGA-A8-A08H-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
OAS3insertionIn_Frame_Insnovelc.369_370insGCCCCCp.Gln123_Ser124insAlaProp.Q123_S124insAPQ9Y6K5protein_codingTCGA-AN-A03X-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
OAS3insertionNonsense_Mutationnovelc.371_372insATGGTGGGAGCTGGAAGTAAAAGGACTGGCATAATp.Ser124ArgfsTer12p.S124Rfs*12Q9Y6K5protein_codingTCGA-AN-A03X-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
OAS3SNVMissense_Mutationrs540377614c.356N>Tp.Thr119Metp.T119MQ9Y6K5protein_codingdeleterious(0.04)benign(0.026)TCGA-2W-A8YY-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinCR
OAS3SNVMissense_Mutationrs769603563c.2369N>Ap.Arg790Glnp.R790QQ9Y6K5protein_codingtolerated(0.51)benign(0.033)TCGA-2W-A8YY-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinCR
OAS3SNVMissense_Mutationc.1382N>Tp.Ser461Leup.S461LQ9Y6K5protein_codingdeleterious(0)probably_damaging(0.987)TCGA-IR-A3LH-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinCR
Page: 1 2 3 4 5 6 7 8 9 10 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1